Recent announcements across the life sciences industry, including new patient-anchored data initiatives, have brought attention to an important question: when companies invest in real-world data (RWD), what actually…

As Datavant builds the agentic AI platform to accelerate the path from data to trusted evidence for Life Sciences organizations, it is critical not only to consider what…

Life Sciences organizations face growing pressure to generate real-world evidence (RWE) faster and at greater scale-for internal decision-making, publication, and external stakeholders, including regulators and payers.Speed is now…

Life Sciences is at an inflection point. Real-world data (RWD) and AI have progressed from pilot programs and proof-of-concept experimentation to core components of clinical development and evidence…

I. The Persistent Execution Gap in RWE Generation in Clinical Development We have previously articulated the case for systematic, integrated RWE generation beginning early in drug development -…

Life sciences organizations have long struggled with fragmented, time-intensive processes for discovering, assessing, and purchasing real-world data (RWD). These bottlenecks delay evidence generation, slow clinical and commercial decision-making,…

For life sciences organizations, medical record retrieval unlocks the “last mile” of real-world data (RWD) – providing access to complete, patient-level records that fill gaps left by traditional…

As digital health outpaces regulation, tokenization offers a scalable path to privacy and trust, enabling advancements that support regulatory, patient, and consumer priorities.